TEST:

Oncomine™ TCR Beta-SR Assay

TCR repertoire profiling could be a potential biomarker for predicting response to durvalumab in NSCLC patients. Our pilot study suggests that measuring the TCR diversity (Evenness) and tracking TCR convergence ratio may be an additional useful parameter for predicting immunotherapy treatment response.

(2021) Early changes in the circulating T cells are associated with clinical outcomes after PD‑L1 blockade by durvalumab in advanced NSCLC patients...Journal of Immunotherapy and Precision Oncology. 2 (4): 137–143.

Here we aim to explore the above TCR repertoire features in peripheral blood of NSCLC patients (with PDL1≥50%) treated with single agent pembrolizumab in the first line setting; and correlate them with overall response rate (ORR), PFS and OS...Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Conclusions Increased pre-treatment TCR clonality and reduced diversity are associated with improved ORR and PFS, but not OS in NSCLC patients with high PD-L1 treated with pembrolizumab monotherapy. Further maturation of this cohort will demonstrate whether the circulating pre-treatment TCR repertoire is a prognostic factor for immunecheckpoint inhibition.

Here, we performed TCR sequencing in patients from the phase 2 trial SAKK 16/14 undergoing neoadjuvant chemotherapy with three cycles of cisplatin / docetaxel followed by treatment with the PD-L1 antibody durvalumab. Our results show that TCR repertoire measured in peripheral blood samples and tumor tissue may provide a useful tool for predicting risk of recurrence after neoadjuvant sequential chemo-immunotherapy with durvalumab in patients with resectable stage IIIA (N2) NSCLC.